A compound of formula I: ADB (I) or a pharmaceutically acceptable salt thereof for use in a method of treating a disease mediated by p38 in a host, the disease being mediated by p38 in a host rheumatoid arthritis, osteoarthritis, arthritis Septic, tumor metastasis, periodontal disease, corneal ulceration, proteinuria, coronary thrombosis caused by rupture of the atherosclerotic plaque, aortic aneurysm, birth control, dystrophic bullous epidermolysis, loss of degenerative cartilage after traumatic joint injury, osteopenias mediated by MMP activity, temperomandibular joint disease, demyelinating disease of the nervous system, rheumatic fever, bone resorption, postmenopausal osteoporosis, septicemia, septicemia by gram negative bacteria, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, intestinal diseases s inflammatory (Crohn's disease and ulcerative colitis), Jarisch-Herxheimer reaction, asthma, respiratory distress syndrome in adults, acute pulmonary fibrotic diseases, pulmonary sarcoidosis, allergic respiratory disease, silicosis, coal miner pneumoconiosis, alveolar lesion , liver failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria (Plasmodium falciparum malaria and cerebral malaria), non-insulin dependent diabetes mellitus (NIDDM), congestive heart failure, damage after heart disease, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis (demyelination and loss of oligodendrocytes in multiple sclerosis), advanced cancer, lymphoid tumor, pancreatitis, altered wound healing in infection, inflammation and cancer, myelodysplastic syndromes, systemic lupus erythematosus, biliary cirrhosis, necrosi s intestinal, psoriasis, radiation / toxicity injury after administration of monoclonal antibodies, host reactions against graft (ischemiarefusion injury and kidney allograft, liver, heart and skin rejections), lung allograft rejection (bronchitis obliterans) ,
